Voyager Therapeutics (STU:VT6) Short Interest

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Voyager Therapeutics's Short Interest

For the Biotechnology subindustry, Voyager Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Short Interest falls into.

Voyager Therapeutics (STU:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines